Valuation: Novartis

Market Cap 284B 249B 229B 213B 404B 27,080B 409B 2,741B 1,067B 13,292B 1,066B 1,043B 46,086B P/E 2026 *
21.6x
P/E 2027 * 18.3x
Enterprise Value 316B 277B 255B 237B 449B 30,134B 455B 3,050B 1,187B 14,792B 1,186B 1,160B 51,285B EV / Sales 2026 *
5.56x
EV / Sales 2027 * 5.18x
Free-Float
91.66%
Yield 2026 *
2.84%
Yield 2027 * 2.93%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 68 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.58% - - 284B
+2.33%+2.93%+59.73%+173.08% 1,070B
+3.60%+5.97%+73.34%+69.00% 624B
+1.07%+2.29%+37.18%+89.96% 450B
+2.14%-2.07%+27.62%+22.57% 328B
+1.87%+1.87%+40.58%+42.08% 292B
+1.98%+4.08%-25.78%-39.02% 217B
+0.65%+1.96%+26.03%+68.85% 198B
+3.63%+6.51%+20.39%+80.83% 161B
+1.62%+0.21%-4.40%-32.09% 135B
Average +1.91%+0.78%+28.30%+52.81% 386.18B
Weighted average by Cap. +2.11%+0.70%+43.04%+86.97%

Financials

2026 *2027 *
Net sales 56.87B 49.8B 45.87B 42.58B 80.86B 5,424B 81.95B 549B 214B 2,663B 214B 209B 9,232B 60.31B 52.82B 48.65B 45.16B 85.75B 5,753B 86.91B 582B 227B 2,824B 226B 222B 9,791B
Net income 14.1B 12.35B 11.38B 10.56B 20.05B 1,345B 20.33B 136B 53B 660B 52.97B 51.8B 2,290B 15.65B 13.7B 12.62B 11.72B 22.25B 1,493B 22.55B 151B 58.8B 733B 58.76B 57.47B 2,540B
Net Debt 32.03B 28.05B 25.83B 23.98B 45.54B 3,055B 46.15B 309B 120B 1,500B 120B 118B 5,199B 28.54B 24.99B 23.02B 21.37B 40.58B 2,722B 41.12B 276B 107B 1,336B 107B 105B 4,633B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA